osteoamp®
Allogeneic Morphogenetic Proteins

Brought to you by bioventus®
Innovations For Active Healing


SPONGE


FIBERS


GRANULES


PUTTY

FLOWABLE (coming soon)

New, Prospective Data for a Uniquely Processed Allograft

Uniquely Processed

OSTEOAMP is a differentiated allograft that is uniquely processed with bone and bone marrow to retain a wide array of growth factors which support each phase of the bone healing cascade.[1]

Multiple Formats

OSTEOAMP is currently offered in putty, granule, sponge and fiber formats. In July, a new Flowable format will be available, adding to the comprehensive Bioventus portfolio.

Existing Clinical Evidence

OSTEOAMP is backed by multiple, peer reviewed, clinical publications which demonstrate positive fusion assessments in a variety of surgical settings. In a large, multicenter, retrospective study of 321 patients that received TLIF or LLIF, it was reported that OSTEOAMP is a viable alternative to Infuse based on fusion rates.[2]

New Clinical Evidence

Two abstracts were presented at the North American Spine Society (NASS) 2020 virtual annual meeting featuring OSTEOAMP in a prospective, posterolateral lumbar fusion study.[3-5] A summary of one of the abstracts is listed below.[5]

Clinical Study Design:

- Prospective (level II evidence)[6]
- 1- and 2-level instrumented posterolateral lumbar fusion (PLF) from L1-S1
- No interbody fusion
- 42 patients enrolled (26 for 1-level, 16 for 2-level)
- Multicenter (9 sites)
- Radiographic (X-ray, CT)
- Clinical outcomes (ODI, VAS, SF-36)

Overview of the Abstract:[5]

- **Title:** *A Novel Bone Graft Has Higher Fusion Rate Than Local Autologous Bone in Stand-alone Posterolateral Fusion: A Propensity Score Adjusted Analysis*
- **OSTEOAMP Group:** 12-month outcomes for 1- and 2-level PLF patients (N = 38)
- **Local Autologous Bone (LAB) Group:** 12-month outcomes for 1-level PLF patients (N = 82) that received local bone only from a large, previously published, randomized controlled trial
- **Propensity Scoring:** Investigators chose the most clinically relevant patient baseline characteristics, including gender, age, BMI, tobacco use, ODI, and VAS back and leg pain.
- **Results:** Fusion, assessed with CTs by two independent and blinded radiologists, was significantly higher for OSTEOAMP (84%) compared to local autologous bone (61%). OSTEOAMP demonstrated high rates of improved patient outcomes, with no product related serious adverse events.

12-MONTH OUTCOMES

	OSTEOAMP	LAB	*p*-value
Fusion	**84%**	**61%**	**0.028 (RR 1.4)**
ODI Score (Improvement)	20.3 (31.5)	18.8 (30.5)	0.7585
SF-36 PCS Improvement	15.4	13.1	0.1642
SF-36 MCS Improvement	7.1	7.6	0.175

CI = 95% *p*-value < 0.05 = statistical significance

References: 1. Bioventus Surgical. Tidwell JL, Seaman SA, Vanderploeg EJ, Tom S. In vitro and in vivo characterization of OSTEOAMP allogeneic morphogenetic proteins. Bioventus white paper. Data on file; 2017. **2.** Roh JS, Yeung CA, Field JS, McClellan RT. Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis. *J Orthop Surg Res.* 2013;8:49. doi:10.1186/1749-799X-8-49 **3.** US National Library of Medicine. A prospective study of instrumented, posterolateral lumbar fusions (PLF) With OsteoAMP®. Last updated November 5, 2020. https://clinicaltrials.gov/ct2/show/NCT02225444 **4.** Daffner SD, Bunch J, An HS, et al. Use of a novel allograft in single-and two-level posterolateral lumbar spinal fusion: two-year clinical and radiographic results from a prospective multicenter study. *Spine J.* 2020;20(suppl 9):S204. Abstract P122. doi:10.1016/j.spinee.2020.05.520 **5.** Daffner SD, Bunch J, An HS, et al. A novel bone graft has higher fusion rate than local autologous bone in stand-alone posterolateral fusion: a propensity score adjusted analysis. *Spine J.* 2020;20(suppl 9):S53-4. Abstract 108. doi:10.1016/j.spinee.2020.05.214 **6.** https://journals.lww.com/jbjsjournal/Pages/Journals-Level-of-Evidence.aspx

For more information, visit **www.bioventussurgical.com**

SMK-003692 03/21